188 related articles for article (PubMed ID: 35777718)
21. Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.
Maryandyshev A; Pontali E; Tiberi S; Akkerman O; Ganatra S; Sadutshang TD; Alffenaar JW; Amale R; Mullerpattan J; Topgyal S; Udwadia ZF; Centis R; D'Ambrosio L; Sotgiu G; Migliori GB
Emerg Infect Dis; 2017 Oct; 23(10):1718-21. PubMed ID: 28758888
[TBL] [Abstract][Full Text] [Related]
22. Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis.
Mallikaarjun S; Chapagain ML; Sasaki T; Hariguchi N; Deshpande D; Srivastava S; Berg A; Hirota K; Inoue Y; Matsumoto M; Hafkin J; Geiter L; Wang X; Gumbo T; Liu Y
Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33106263
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB.
Millard J; Rimmer S; Nimmo C; O'Donnell M
Emerg Infect Dis; 2023 May; 29(5):1081-1084. PubMed ID: 37081529
[TBL] [Abstract][Full Text] [Related]
24. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
25. Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician's perspective.
Guglielmetti L; Chiesi S; Eimer J; Dominguez J; Masini T; Varaine F; Veziris N; Ader F; Robert J
Future Microbiol; 2020 Jun; 15():779-799. PubMed ID: 32700565
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
27. Discovery and preclinical profile of sudapyridine (WX-081), a novel anti-tuberculosis agent.
Huang Z; Luo W; Xu D; Guo F; Yang M; Zhu Y; Shen L; Chen S; Tang D; Li L; Li Y; Wang B; Franzblau SG; Ding CZ
Bioorg Med Chem Lett; 2022 Sep; 71():128824. PubMed ID: 35636648
[TBL] [Abstract][Full Text] [Related]
28. Multidrug Resistant Tuberculosis With Simultaneously Acquired Drug Resistance to Bedaquiline and Delamanid.
Yoshiyama T; Takaki A; Aono A; Mitarai S; Okumura M; Ohta K; Kato S
Clin Infect Dis; 2021 Dec; 73(12):2329-2331. PubMed ID: 32730621
[TBL] [Abstract][Full Text] [Related]
29. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
Yang JS; Kim KJ; Choi H; Lee SH
Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
[TBL] [Abstract][Full Text] [Related]
30. Six-Month Response to Delamanid Treatment in MDR TB Patients.
Hewison C; Ferlazzo G; Avaliani Z; Hayrapetyan A; Jonckheere S; Khaidarkhanova Z; Mohr E; Sinha A; Skrahina A; Vambe D; Vasilyeva I; Lachenal N; Varaine F
Emerg Infect Dis; 2017 Oct; 23(10):1746-8. PubMed ID: 28767036
[TBL] [Abstract][Full Text] [Related]
31. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
Pontali E; Visca D; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
Curr Opin Pulm Med; 2018 May; 24(3):244-252. PubMed ID: 29470252
[TBL] [Abstract][Full Text] [Related]
32. Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China.
Zhang Q; Liu Y; Tang S; Sha W; Xiao H
Cell Biochem Biophys; 2013; 67(3):957-63. PubMed ID: 23546935
[TBL] [Abstract][Full Text] [Related]
33. Management of drug resistantTB in patients with HIV co-infection.
Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945
[TBL] [Abstract][Full Text] [Related]
34. Unraveling Dilemmas and Lacunae in the Escalating Drug Resistance of
Negi A; Perveen S; Gupta R; Singh PP; Sharma R
J Med Chem; 2024 Feb; 67(4):2264-2286. PubMed ID: 38351709
[TBL] [Abstract][Full Text] [Related]
35. Delamanid (OPC-67683) for treatment of multi-drug-resistant tuberculosis.
Sotgiu G; Pontali E; Centis R; D'Ambrosio L; Migliori GB
Expert Rev Anti Infect Ther; 2015 Mar; 13(3):305-15. PubMed ID: 25645397
[TBL] [Abstract][Full Text] [Related]
36. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
37. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.
Skripconoka V; Danilovits M; Pehme L; Tomson T; Skenders G; Kummik T; Cirule A; Leimane V; Kurve A; Levina K; Geiter LJ; Manissero D; Wells CD
Eur Respir J; 2013 Jun; 41(6):1393-400. PubMed ID: 23018916
[TBL] [Abstract][Full Text] [Related]
38. Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment.
Polsfuss S; Hofmann-Thiel S; Merker M; Krieger D; Niemann S; Rüssmann H; Schönfeld N; Hoffmann H; Kranzer K
Clin Infect Dis; 2019 Sep; 69(7):1229-1231. PubMed ID: 30933266
[TBL] [Abstract][Full Text] [Related]
39. Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
Bonnet M; Bastard M; du Cros P; Khamraev A; Kimenye K; Khurkhumal S; Hayrapetyan A; Themba D; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F
Int J Tuberc Lung Dis; 2016 Feb; 20(2):177-86. PubMed ID: 26792469
[TBL] [Abstract][Full Text] [Related]
40. Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST.
Keller PM; Hömke R; Ritter C; Valsesia G; Bloemberg GV; Böttger EC
Antimicrob Agents Chemother; 2015 Jul; 59(7):4352-5. PubMed ID: 25941226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
